GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicamen Biotech Ltd (NSE:MEDICAMEQ) » Definitions » Debt-to-Equity

Medicamen Biotech (NSE:MEDICAMEQ) Debt-to-Equity : N/A (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Medicamen Biotech Debt-to-Equity?

Medicamen Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Medicamen Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Medicamen Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2024 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Medicamen Biotech's Debt-to-Equity or its related term are showing as below:

NSE:MEDICAMEQ' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04   Med: 0.15   Max: 1.21
Current: 0.09

During the past 13 years, the highest Debt-to-Equity Ratio of Medicamen Biotech was 1.21. The lowest was 0.04. And the median was 0.15.

NSE:MEDICAMEQ's Debt-to-Equity is ranked better than
72.67% of 816 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs NSE:MEDICAMEQ: 0.09

Medicamen Biotech Debt-to-Equity Historical Data

The historical data trend for Medicamen Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicamen Biotech Debt-to-Equity Chart

Medicamen Biotech Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.14 0.18 0.13 0.15

Medicamen Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.15 N/A 0.09 N/A

Competitive Comparison of Medicamen Biotech's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicamen Biotech's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicamen Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Medicamen Biotech's Debt-to-Equity falls into.


;
;

Medicamen Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Medicamen Biotech's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Medicamen Biotech's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicamen Biotech  (NSE:MEDICAMEQ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Medicamen Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Medicamen Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicamen Biotech Business Description

Traded in Other Exchanges
Address
1506, Chiranjiv Tower, 43, Nehru Place, New Delhi, IND, 110019
Medicamen Biotech Ltd is an Indian based pharmaceutical company. The company is engaged in developing and manufacturing Pharmaceuticals formulations products. It manufactures Tablets, Capsules, Oral liquids, Dry syrups, Ointments, and Oral rehydration solution. The company generates revenue from the sale of pharmaceutical products.

Medicamen Biotech Headlines

No Headlines